Cipla Medpro

• 

  Cipla Ties Up With Serum Institute to Sell Vaccines in South Africa

  Cipla Ltd, India's fourth largest drug maker by sales, said on Thursday it had agreed to an exclusive deal with Serum Institute of India to supply vaccines to South Africa, adding a new market to their partnership in India and Europe.

• Cipla Bags Rs 1,100 Crore Deal in South Africa

  Drug major Cipla's subsidiary - Cipla Medpro - has bagged an order worth 2 billion rands (around Rs 1,100 crore) for HIV drugs from the South African government.

• Cipla Unit Gets Rs 195 Contract From South Africa

  Cipla Medpro, the South African subsidiary of the Indian firm, has been awarded a 345 million rand share of the South African government's national respiratory tender, the company said in a statement.

• Cipla spends Rs 274 crore to set up API facilities

  The Patalganga project for the upgradation and scale-up of API facilities is nearing completion. It is anticipated that operations will commence during 2013-14. The company is also scaling up its anti-cancer formulations facility at Goa.

• Cipla says to prioritise African markets for growth

  Cipla CEO Subhanu Saxena cited analysts' predictions that the African pharmaceutical market would grow to between $30-40 billion by 2020.

• Cipla Medpro shareholders back buyout by India's Cipla

  Shareholders of South Africa's Cipla Medpro overwhelmingly approved a $488 million takeover offer from India's Cipla Ltd on Wednesday, giving the Indian drugmaker a big presence in Africa's biggest economy.

• Cipla bids $500 million for South Africa affiliate

  Drugmaker Cipla Ltd offered over $500 million to buy out South African affiliate Cipla Medpro on Thursday, sweetening its bid by 17 per cent after earlier talks stalled over price.

• Cipla plans $512 million takeover of South Africa's Cipla Medpro

  Cipla Ltd on Thursday sweetened its offer by 17 per cent to take over South Africa's third-largest drug-maker, Cipla Medpro South Africa Ltd, ending the uncertainty of an earlier offer that had been put on hold by the Indian company.

• Cipla puts $215 million South Africa bid on hold

  Cipla has put on hold a $215 million bid for control of South African generic drug firm Cipla Medpro, the chairman of the drug maker said on Monday.

• Will pharma stocks be fourth-time lucky in 2013?

  The BSE Healthcare Index has outperformed the Sensex over the past three years on the back of strong earnings by pharma companies. Two analysts at Nomura - Saion Mukherjee and Aditya Khemka - met nearly 40 investors in Asia and the U.S. to find 10 trends in the pharma sector.

• Cipla gains on partner's contract win

  Shares in drugmaker Cipla rose 1.4 per cent after Cipla Medpro won a share in South Africa's $667 million contract, as it supplies the bulk of Cipla Medpro's drugs.

• Cipla to buy 51 per cent stake in South Africa's Cipla Medpro

  Indian drugs maker Cipla Limited has offered to buy a about a 51 percent stake in South Africa's Cipla Medpro, to strengthen its position in the fast-growing African drugs market.